Streck expands Protein Plus BCT to cover cfDNA and cfRNA
Streck has announced the launch of Nucleic Acid Plus BCT, a blood collection tube designed to stabilize cell-free DNA (cfDNA), cell-free RNA (cfRNA), extracellular vesicles (EVs) and select plasma proteins from a single blood draw.
Formerly known as Protein Plus BCT, this product has expanded its intended use claims to include cfDNA and cfRNA alongside EVs and plasma proteins to better suit downstream multi-analyte applications.
Nucleic Acid Plus BCT provides stabilization of whole blood samples at ambient temperature (18 °C to 25 °C), with cfDNA and cfRNA remaining stable in stored samples for up to 7 days and EVs and select plasma proteins remaining stable for up to 5 days. This allows for multi-analyte analysis from a single draw.
The tube’s proprietary preservative reagent stabilizes nucleated blood cells, red blood cells and platelets while minimizing ex vivo hemolysis and platelet activation. This limits the release of genomic DNA, RNA, EVs and proteins from blood cells during whole blood storage, helping maintain draw-time plasma profile and reducing pre-analytical variability caused by shipping delays, sample batching or extended transit times.
Nucleic Acid Plus BCT is available as a 5 mL configuration in packs of 6, boxes of 100 or cases of 1000 (Cat. No’s 230698, 230699, 230700, respectively) to support streamlined logistics across decentralized sites of all sizes. A 10 mL configuration of Nucleic Acid BCT is expected to launch later this year.
Nucleic Acid Plus BCT is for Research Use Only. Not for use in diagnostic procedures.
